Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$33.68 USD
-0.48 (-1.41%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $33.73 +0.05 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum C VGM
Earnings News For MIRM
-
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
-
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
-
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
-
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
-
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
-
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
-
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
-
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue Estimates
-
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
-
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss
-
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Misses Revenue Estimates